Full-Time
Delivers AI-powered, patient-centered healthcare experiences
$119k - $140k/yr
New Hope, PA, USA + 4 more
More locations: Boston, MA, USA | Chicago, IL, USA | Carmel, IN, USA | United States
Hybrid
Two days per week in-office attendance required for employees within one-hour commute of an office.
See people who can refer or advise you
Real Chemistry helps healthcare brands grow by creating AI-powered, customer-centered healthcare experiences. It combines AI-enabled experiences with cross-disciplinary teams to design and deliver programs across patient, provider, and payer touchpoints. The company differentiates itself through large, integrated teams of specialists focused exclusively on healthcare and customer experience under one mission. Its goal is to transform how healthcare is experienced while driving commercial success for healthcare organizations.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
San Francisco, California
Founded
2001
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Wellness Program
Mental Health Support
Paid Vacation
mea Platform appoints Robin Tolla as chief human resources officer. mea Platform has appointed Robin Tolla (pictured) as chief human resources officer, with the former Axa XL human resources executive joining the insurance-focused artificial intelligence company to lead its global people strategy as it continues to expand across Europe, Asia and the Americas. Tolla brings more than 30 years of human resources leadership experience, including more than 15 years in the insurance and technology sectors. Her expertise spans people strategy, organisational design and merger and acquisition integration. Her appointment follows a period of rapid recruitment at mea, with the company adding employees across engineering, product, client delivery and client solutions. The company said Tolla will help support its continued growth and product development. Before joining mea, Tolla was co-chief people officer at healthcare communications and technology company Real Chemistry. Earlier, she spent seven years at XL Group, later Axa XL, where she held a series of senior HR leadership roles, including vice president of HR supporting the chief operating officer of the combined XL Catlin business. During her tenure, she led HR integration work across major acquisitions and helped design operating models for the Axa XL integration. Martin Henley, chief executive officer of mea, said: "Throughout her career in the insurance and technology industries, Robin has designed operating models and led M&A integrations inside the exact environments we now serve. Time and time again, she has showcased her ability to build organisations that absorb fast growth and turn it into business performance. That insurance pedigree, combined with her operational discipline, is precisely what mea needs at this stage." Tolla said: "The best insurance operators have always known that people are what make the difference, and that has not changed with AI; it has only raised the stakes. mea has built technology that owns the repeatable work and elevates talented people to the decisions that matter. Shaping the culture and organisation behind the company reimagining insurance operations is something I am honoured to be a part of." Editor's picks. Re/insurance 12 June 2026 Re/insurance 5 June 2026 Re/insurance 5 June 2026 Re/insurance 4 June 2026 Re/insurance 1 June 2026 Re/insurance 29 May 2026
Real Chemistry launches Real Chemistry ANATOMI, an AI Ecosystem purpose-built for Healthcare Commercialization. The unique combination of technology marks 25 years of industry innovation and expertise, and signals company's next phase of business growth and client value NEW YORK - Real Chemistry, a global leade AI News Generator July 15, 2026 Title: Real Chemistry Unveils ANATOMI: A New AI Ecosystem Revolutionizing Healthcare Commercialization Excerpt: Real Chemistry launches ANATOMI, an AI ecosystem built for healthcare commercialization, combining 25 years of industry expertise with cutting-edge technology. Discover how this AI Prompt-driven platform is set to transform client value and business growth. In a landmark move that bridges decades of industry wisdom with next-generation technology, Real Chemistry has officially launched Real Chemistry ANATOMI - an AI ecosystem purpose-built for healthcare commercialization. The announcement, made from New York, marks 25 years of the company's leadership in AI-driven insights, marketing, and communications, signaling a new phase of business growth and enhanced client value. ANATOMI is not just another AI tool; it's a comprehensive ecosystem designed to address the unique complexities of healthcare commercialization. By integrating advanced machine learning, natural language processing, and predictive analytics, the platform aims to streamline how pharmaceutical and biotech companies bring therapies to market. The name itself - ANATOMI - reflects a deep, structural understanding of the healthcare landscape, from patient journeys to provider engagement. The timing is critical. Healthcare commercialization has long been hampered by fragmented data, siloed teams, and regulatory hurdles. Real Chemistry's solution leverages its 25-year track record to create a unified, intelligent system. For instance, when a marketing team needs to craft a campaign around a new oncology drug, they can use an AI Prompt to generate culturally sensitive messaging, analyze competitor strategies, and predict patient adherence - all within a single interface. This integration of an AI Prompt into the workflow ensures that even non-technical users can extract actionable insights without needing a data science background. "We've spent two and a half decades understanding the nuances of healthcare communications," said a Real Chemistry spokesperson. "ANATOMI is the culmination of that expertise, combined with the scalability of AI. It's designed to help our clients navigate the 'valley of death' in drug commercialization - from approval to market access." Key features of ANATOMI include: * Real-time Data Fusion: Aggregates clinical trial data, real-world evidence, and social listening to provide a 360-degree view of a therapy's potential. * Predictive Modeling: Uses historical patterns to forecast market adoption, pricing pressures, and physician prescribing behavior. * Compliance Guardrails: Automatically flags content that may violate FDA or EMA regulations, reducing legal risks. * Personalization at Scale: Generates tailored messages for HCPs, payers, and patients using dynamic content algorithms. What sets ANATOMI apart is its focus on "purpose-built" AI. Unlike generic AI solutions, it's trained on proprietary healthcare datasets spanning 25 years, including de-identified patient narratives, clinical guidelines, and campaign performance metrics. This specialization means the platform understands the emotional and regulatory weight of healthcare messaging - a nuance often missed by off-the-shelf models. The launch also reflects a broader trend: the convergence of marketing technology and life sciences. As healthcare companies face pressure to prove ROI and improve patient outcomes, AI ecosystems like ANATOMI offer a competitive edge. For example, a brand manager could use an AI Prompt to simulate how a new diabetes drug might be perceived by endocrinologists versus primary care physicians, adjusting the strategy in minutes rather than weeks. Real Chemistry's move positions it as a frontrunner in the healthcare AI space, competing with giants like IQVIA and Accenture but with a sharper focus on creative and communications. The company's existing client roster - including top-20 pharma firms - suggests immediate traction. For businesses looking to stay ahead, ANATOMI underscores a key lesson: AI is only as powerful as the domain expertise behind it. By embedding an AI Prompt system that learns from 25 years of healthcare intelligence, Real Chemistry is not just automating tasks - it's redefining how the industry thinks about commercialization. As the healthcare landscape evolves, ANATOMI may well become the standard for how therapies are brought to life, from lab bench to bedside.
Real Chemistry announces new Asia Pacific hub with acquisition of Spurwing Communications in Singapore. Business Wire Published Jul 06, 2026 Article content Expanded footprint advances the company's global strategy in key growth region for healthcare and pharma brands Article content SINGAPORE - Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company's first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry's global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support - ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. Article content Advertisement 1 Story continues below This advertisement has not loaded yet, but your article continues below. Article content "APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies," said Kath Harrison, Group President, International Growth at Real Chemistry. "By bringing Spurwing into Real Chemistry, we're expanding our presence in the region and deepening our ability to help clients drive measurable impact by delivering more connected, data-driven and culturally relevant engagement across these key markets." Article content Top Stories Interested in more newsletters? Browse here. Article content Founded in Singapore, Spurwing Communications is a leading agency with an established track record advising pharmaceutical and healthcare organizations - as well as clients across a broader range of industries - throughout APAC. The company is known for high-impact strategic counsel across integrated communications, medical affairs and its nuanced understanding of the region's diverse and evolving market environments. Article content Emma Thompson, Founder and Chief Executive Officer (CEO) of Spurwing Communications, will continue to lead the business as President, APAC Growth, reporting to Harrison. "Joining Real Chemistry allows us to broaden what we can offer clients, while staying grounded in the strong regional expertise and senior counsel for which our clients value us," said Thompson. "I'm extremely proud of what we have achieved as a team and excited for the next phase of our growth as part of Real Chemistry. We will continue to support our existing clients while expanding our APAC presence and adding capabilities - including analytics and AI - to enhance our connected, comprehensive regional offerings." Article content "Real Chemistry's acquisition of Spurwing Communications is an important step in our global growth strategy," said Shankar Narayanan, CEO of Real Chemistry. "We're continuing to invest in the capabilities and regions that matter most to our clients as they navigate growing global commercialization challenges. Strengthening our presence in APAC allows us to better support clients across the full lifecycle - from strategy through engagement - in one of the most dynamic healthcare markets in the world." Article content Additional hires and market expansion plans are expected to be announced over the coming months, as Real Chemistry continues to scale its regional hub model and affiliate network across key international markets. Article content About Real Chemistry: 25 Years of Future-Focused Healthcare Article content Advertisement 2 Story continues below This advertisement has not loaded yet, but your article continues below. Article content Celebrating its 25th anniversary this year, Real Chemistry is a tier-one commercialization partner to the world's most innovative life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, Real Chemistry helps the healthcare industry better understand, reach and engage critical audiences to improve the healthcare experience for all. Anchored by a culture of innovation and creativity, Real Chemistry's 2,400+ global experts across life sciences, marketing communications and technology are singularly focused on navigating the complexities of bringing scientific advances to market - and to the people who need them most. Real Chemistry's brand portfolio includes 21GRAMS, a highly awarded creative agency, and starpower, a celebrity and influencer practice. Article content Today, Real Chemistry operates through offices across North America, Europe, the Middle East and Asia Pacific, complemented by a strategic partner network in Latin America and Africa - enabling the company to support clients wherever they operate. Article content View source version on businesswire.com: Article content Advertisement 1 This advertisement has not loaded yet.
Real Chemistry, an AI-driven marketing and communications firm serving healthcare and life sciences sectors, has appointed Frank Clyburn and Chris Fikry as non-executive board members. Clyburn brings pharmaceutical commercialisation expertise, having served as CEO of International Flavors & Fragrances and held leadership roles at Merck, including overseeing the Keytruda franchise. He currently serves on the boards of Cencora, Revolution Medicines and Kailera Therapeutics. Fikry brings experience in data and technology-enabled life sciences businesses. He served as CEO of Clario, a clinical trial endpoint data solutions provider acquired by Thermo Fisher Scientific in 2026, and was President of Laboratory Services at PPD. The appointments strengthen Real Chemistry's position as it celebrates its 25th anniversary, operating with 2,400 global experts across North America, Europe and the Middle East.
Real Chemistry, a global healthcare communications firm, has appointed four senior international leaders and expanded its regional hub presence as part of its global growth strategy. The company is opening new offices in Munich, Zurich and Dubai, with further expansion planned. The appointments include Kath Harrison as Group President, International Growth; Brandon Pletsch as President, Europe; Louise Clark as President, Integrated Communications, Global; and Eleanor Read as President, Integrated Communications, Europe. The leaders bring decades of experience advising global pharmaceutical companies. Since 2023, Real Chemistry's international team has grown 25%, with over 300 employees now working outside the United States. The expansion aims to support healthcare clients navigating complex multi-market environments across Europe, the Middle East, Asia Pacific and Latin America.